China’s NMPA approves AstraZeneca and Merck’s Lynparza for ovarian cancer
A PARP inhibitor, Lynparza is the first targeted treatment, which is designed to inhibit DNA damage response (DDR) in cells/tumours which harbour deficiency in homologous recombination repair (HRR),
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.